AU2009246114B2 - Treating dyspnea associated with acute heart failure with relaxin - Google Patents

Treating dyspnea associated with acute heart failure with relaxin Download PDF

Info

Publication number
AU2009246114B2
AU2009246114B2 AU2009246114A AU2009246114A AU2009246114B2 AU 2009246114 B2 AU2009246114 B2 AU 2009246114B2 AU 2009246114 A AU2009246114 A AU 2009246114A AU 2009246114 A AU2009246114 A AU 2009246114A AU 2009246114 B2 AU2009246114 B2 AU 2009246114B2
Authority
AU
Australia
Prior art keywords
relaxin
day
heart failure
subject
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009246114A
Other languages
English (en)
Other versions
AU2009246114A1 (en
Inventor
Gad Cotter
Dennis R. Stewart
Sam L. Teichman
Elaine Unemori
Martha Jo Whitehouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corthera Inc
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of AU2009246114A1 publication Critical patent/AU2009246114A1/en
Application granted granted Critical
Publication of AU2009246114B2 publication Critical patent/AU2009246114B2/en
Priority to AU2013201629A priority Critical patent/AU2013201629B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009246114A 2008-05-16 2009-05-15 Treating dyspnea associated with acute heart failure with relaxin Ceased AU2009246114B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013201629A AU2013201629B2 (en) 2008-05-16 2013-03-19 Treating dyspnea associated with acute heart failure with relaxin

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US61/127,889 2008-05-16
US19054508P 2008-08-28 2008-08-28
US61/190,545 2008-08-28
US20124008P 2008-12-08 2008-12-08
US61/201,240 2008-12-08
US16433309P 2009-03-27 2009-03-27
US61/164,333 2009-03-27
PCT/US2009/044249 WO2009140659A2 (en) 2008-05-16 2009-05-15 Method of treating dyspnea associated with acute heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013201629A Division AU2013201629B2 (en) 2008-05-16 2013-03-19 Treating dyspnea associated with acute heart failure with relaxin

Publications (2)

Publication Number Publication Date
AU2009246114A1 AU2009246114A1 (en) 2009-11-19
AU2009246114B2 true AU2009246114B2 (en) 2013-01-31

Family

ID=40834101

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009246114A Ceased AU2009246114B2 (en) 2008-05-16 2009-05-15 Treating dyspnea associated with acute heart failure with relaxin

Country Status (30)

Country Link
US (7) US8053411B2 (OSRAM)
EP (2) EP2288373B1 (OSRAM)
JP (4) JP5651586B2 (OSRAM)
CN (3) CN103212063B (OSRAM)
AR (1) AR071810A1 (OSRAM)
AU (1) AU2009246114B2 (OSRAM)
BR (1) BRPI0913011A2 (OSRAM)
CA (1) CA2724540C (OSRAM)
CR (1) CR11749A (OSRAM)
CY (1) CY1116925T1 (OSRAM)
DK (1) DK2288373T3 (OSRAM)
EA (2) EA022948B1 (OSRAM)
ES (1) ES2546287T3 (OSRAM)
GB (2) GB2459983B (OSRAM)
HK (1) HK1202054A1 (OSRAM)
HR (1) HRP20150845T1 (OSRAM)
HU (1) HUE025483T2 (OSRAM)
IL (3) IL208992A (OSRAM)
MA (1) MA32389B1 (OSRAM)
MX (1) MX2010012450A (OSRAM)
MY (2) MY159803A (OSRAM)
NZ (3) NZ701038A (OSRAM)
PL (1) PL2288373T3 (OSRAM)
PT (1) PT2288373E (OSRAM)
SG (2) SG191587A1 (OSRAM)
SI (1) SI2288373T1 (OSRAM)
TW (1) TWI386202B (OSRAM)
UA (1) UA99953C2 (OSRAM)
WO (1) WO2009140659A2 (OSRAM)
ZA (1) ZA201007449B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071810A1 (es) 2008-05-16 2010-07-14 Corthera Inc Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.
WO2009140657A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating chronic heart failure
RU2564900C2 (ru) * 2010-03-10 2015-10-10 Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Модулирование аквапоринов релаксином
US8501418B2 (en) 2010-08-06 2013-08-06 Pronata N.V. Method of treating renal dysfunction based on perlecan as a biomarker
EP3572091B1 (en) 2010-08-17 2023-12-13 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
CN103930440A (zh) * 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
KR102107482B1 (ko) * 2012-02-14 2020-05-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 심혈관 질환 및 다른 증상에 대한 파라크린 유전자의 전신 전달 및 조절 발현
EP2844345B1 (en) 2012-05-04 2022-08-03 The United States of America, as Represented by The Secretary, Department of Health and Human Services Modulators of the relaxin receptor 1
EP2925128B1 (en) 2012-10-26 2018-04-11 Chiesi Farmaceutici S.p.A. Methods for controlling blood pressure and reducing dyspnea in heart failure
EP2981258B8 (en) * 2013-04-05 2020-11-11 scPharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EA201691562A2 (ru) * 2014-02-03 2017-01-30 Новартис Аг Фильтры для инфузионных наборов
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
AU2015273097A1 (en) * 2014-06-13 2016-11-17 Novartis Ag Use of serelaxin to reduce GDF-15
EP4011919A3 (en) 2015-12-09 2022-10-12 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
EP3413783B1 (en) 2016-02-12 2025-01-22 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
WO2018148419A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
WO2020120482A1 (en) 2018-12-10 2020-06-18 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
CN113271923B (zh) 2019-01-04 2025-05-13 Sq创新股份公司 呋塞米的药物组合物及其用途
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
CN119947743A (zh) 2022-08-31 2025-05-06 雷拉科斯拉制药有限责任公司 免疫抑制药物及治疗方法
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
WO2002040500A2 (en) * 2000-11-16 2002-05-23 Immundiagnostik Ag Method of prognosis and diagnosis of congestive heart failure

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
EP0707650B1 (en) 1993-06-21 2003-05-21 Genentech, Inc. Process for producing human relaxin
EP0675732B1 (en) 1993-07-27 2006-06-28 Mario Bigazzi Use of relaxin in the manufacture of therapeutic agents
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
CA2229479C (en) 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
DE60128540T2 (de) * 2000-02-09 2008-01-31 Bas Medical, Inc., San Mateo Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1729817B1 (en) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
WO2007008907A2 (en) * 2005-07-11 2007-01-18 Abbott Laboratories Methods for determining how to treat congestive heart failure
JP5355561B2 (ja) 2007-07-12 2013-11-27 コンピュゲン エルティーディー． 生物活性ペプチドおよびその使用方法
WO2009140657A2 (en) 2008-05-16 2009-11-19 Corthera, Inc. Method of treating chronic heart failure
AR071810A1 (es) * 2008-05-16 2010-07-14 Corthera Inc Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
WO2002040500A2 (en) * 2000-11-16 2002-05-23 Immundiagnostik Ag Method of prognosis and diagnosis of congestive heart failure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"View of NCT00520806 on 2008_04_23" [retrieved on 7 September 2011] Retrieved from the internet published 23 April 2008 *

Also Published As

Publication number Publication date
IL228244A (en) 2016-10-31
JP2016053040A (ja) 2016-04-14
US9579363B2 (en) 2017-02-28
US20130116181A1 (en) 2013-05-09
EA022948B1 (ru) 2016-03-31
TWI386202B (zh) 2013-02-21
SI2288373T1 (sl) 2015-12-31
GB0918132D0 (en) 2009-12-02
US20170151311A1 (en) 2017-06-01
US20120040903A1 (en) 2012-02-16
JP5651586B2 (ja) 2015-01-14
JP2013040174A (ja) 2013-02-28
MY159803A (en) 2017-02-15
EP2288373A2 (en) 2011-03-02
MX2010012450A (es) 2011-03-21
CA2724540C (en) 2014-07-08
CA2724540A1 (en) 2009-11-19
MY158327A (en) 2016-09-30
GB2459983B (en) 2010-04-28
IL208992A0 (en) 2011-01-31
HUE025483T2 (en) 2016-02-29
JP5638044B2 (ja) 2014-12-10
GB2462221B (en) 2010-09-01
EA201001771A1 (ru) 2011-06-30
US20120040902A1 (en) 2012-02-16
US9205132B2 (en) 2015-12-08
AR071810A1 (es) 2010-07-14
EP2829280A1 (en) 2015-01-28
BRPI0913011A2 (pt) 2019-09-03
PT2288373E (pt) 2015-10-19
ES2546287T3 (es) 2015-09-22
SG10201609580YA (en) 2016-12-29
US8372809B2 (en) 2013-02-12
IL208992A (en) 2013-09-30
HK1187550A1 (zh) 2014-04-11
HK1139051A1 (en) 2010-09-10
WO2009140659A3 (en) 2010-07-22
PL2288373T3 (pl) 2015-11-30
GB2459983A (en) 2009-11-18
EA201500552A1 (ru) 2016-07-29
NZ701038A (en) 2016-01-29
US8415301B2 (en) 2013-04-09
AU2009246114A1 (en) 2009-11-19
JP2015013870A (ja) 2015-01-22
CR11749A (es) 2011-02-11
CN106177914A (zh) 2016-12-07
HRP20150845T1 (hr) 2015-11-06
DK2288373T3 (en) 2015-09-28
CN103212063B (zh) 2015-07-22
WO2009140659A2 (en) 2009-11-19
CN103212063A (zh) 2013-07-24
HK1140693A1 (en) 2010-10-22
HK1151229A1 (en) 2012-01-27
HK1202054A1 (en) 2015-09-18
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
GB0908432D0 (en) 2009-06-24
GB2462221A (en) 2010-02-03
TW200948353A (en) 2009-12-01
CN102036679A (zh) 2011-04-27
US8053411B2 (en) 2011-11-08
EP2288373B1 (en) 2015-06-24
US20150320834A1 (en) 2015-11-12
NZ598709A (en) 2013-09-27
JP2011520918A (ja) 2011-07-21
JP5875646B2 (ja) 2016-03-02
US20130210730A1 (en) 2013-08-15
UA99953C2 (uk) 2012-10-25
ZA201007449B (en) 2011-06-29
US9066916B2 (en) 2015-06-30
IL247351A0 (en) 2016-09-29
CY1116925T1 (el) 2017-04-05
SG191587A1 (en) 2013-07-31
US20100048475A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
AU2009246114B2 (en) Treating dyspnea associated with acute heart failure with relaxin
AU2009246112B2 (en) Method of treating chronic heart failure
AU2013201629A1 (en) Treating dyspnea associated with acute heart failure with relaxin
HK1151229B (en) Relaxin for use in treating of dyspnea associated with acute heart failure
HK1187550B (en) Treating dyspnea associated with acute heart failure with relaxin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired